Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?

Literature DB >> 32675841

PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?

Christie M Ballantyne¹.
1. HOUSTON, TEXAS.

Abstract

In this manuscript, I will discuss where we stand in 2019, with a focus on inflammation and lipids, in regard to precision medicine for cardiovascular disease prevention. This manuscript will reflect my career journey working in the cardiovascular disease field.

Entities: Chemical Disease

Year: 2020 PMID： 32675841 PMCID： PMC7358503

Source DB: PubMed Journal: Trans Am Clin Climatol Assoc ISSN： 0065-7778

Keyword Cloud
References

22 in total

Review 1. Getting to the site of inflammation: the leukocyte adhesion cascade updated.

Authors: Klaus Ley; Carlo Laudanna; Myron I Cybulsky; Sussan Nourshargh
Journal: Nat Rev Immunol Date: 2007-09 Impact factor: 53.106

2. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Authors: Christie M Ballantyne; Harold E Bays; John J Kastelein; Evan Stein; Jonathan L Isaacsohn; Rene A Braeckman; Paresh N Soni
Journal: Am J Cardiol Date: 2012-07-20 Impact factor: 2.778

3. CD11c/CD18 Signals Very Late Antigen-4 Activation To Initiate Foamy Monocyte Recruitment during the Onset of Hypercholesterolemia.

Authors: Greg A Foster; Lu Xu; Alagu A Chidambaram; Stephanie R Soderberg; Ehrin J Armstrong; Huaizhu Wu; Scott I Simon
Journal: J Immunol Date: 2015-10-30 Impact factor: 5.422

4. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors: Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal: N Engl J Med Date: 2017-08-27 Impact factor: 91.245

5. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne
Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245

6. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal: Lancet Date: 2005-09-27 Impact factor: 79.321

10. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal: Lancet Date: 2010-11-08 Impact factor: 79.321